The Incretin based Drugs Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Drug (Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others).
In 2024, the market for incretin-based drugs continues to be a significant therapeutic option in the management of type 2 diabetes mellitus, offering novel pharmacological approaches to improve glycemic control and reduce the risk of cardiovascular complications. Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), leverage the physiological actions of incretin hormones to enhance insulin secretion, suppress glucagon release, and promote satiety, leading to improved blood glucose levels and weight management. These drugs are administered orally or by injection and are often prescribed as adjunctive therapy to other antidiabetic medications or as monotherapy in patients unable to tolerate or achieve glycemic targets with conventional therapies. The market for incretin-based drugs continues to expand with the introduction of new agents, combination therapies, and extended-release formulations aimed at improving treatment adherence, efficacy, and patient outcomes. Furthermore, ongoing research into the cardiometabolic effects and long-term safety of incretin-based therapies underscores their role as valuable treatment options in the management of type 2 diabetes mellitus. With the increasing prevalence of diabetes and the emphasis on personalized treatment approaches, the incretin-based drugs market is poised for continued growth and innovation, providing patients and healthcare providers with effective tools for diabetes management.
Incretin-based drugs market is experiencing a prominent trend toward personalized medicine and precision therapeutics. With advancements in genomic technologies and an understanding of individual variability in drug response, there is a shift towards tailoring treatments to the specific needs and characteristics of patients. Incretin-based drugs, such as GLP-1 receptor agonists and DPP-4 inhibitors, offer favorable efficacy and safety profiles for managing type 2 diabetes mellitus. The trend toward personalized medicine in diabetes care involves optimizing treatment regimens based on factors like genetic predisposition, metabolic profiles, and lifestyle factors, ultimately leading to improved patient outcomes and treatment adherence.
A key driver for the incretin-based drugs market is the escalating prevalence of diabetes and metabolic disorders worldwide. Factors such as sedentary lifestyles, unhealthy dietary habits, obesity, and an aging population contribute to the growing burden of diabetes mellitus and related complications. Incretin-based therapies provide effective glycemic control, promote weight loss, and have a lower risk of hypoglycemia compared to traditional antidiabetic agents. As the incidence of diabetes continues to rise, there is an increasing demand for innovative treatment options, driving market growth for incretin-based drugs.
An emerging opportunity in the incretin-based drugs market lies in the expansion into adjacent therapeutic areas and emerging markets. While incretin-based therapies are primarily used in the management of type 2 diabetes, there is potential for their application in other metabolic disorders such as obesity and non-alcoholic fatty liver disease (NAFLD). Additionally, expanding into emerging markets presents an opportunity for market players to address unmet medical needs and tap into growing patient populations. Factors such as improving healthcare infrastructure, rising disposable incomes, and increasing awareness about diabetes and its complications offer a conducive environment for market penetration in emerging economies. By strategically expanding their product portfolios and geographic presence, companies can capitalize on these opportunities to drive revenue growth and enhance their market position in the global landscape of incretin-based drugs.
In the Incretin-based Drugs Market, the segment experiencing the fastest growth is Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. GLP-1 receptor agonists are a class of medications used in the management of type 2 diabetes mellitus. They work by mimicking the action of the natural hormone GLP-1, which stimulates insulin secretion, inhibits glucagon release, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists are available in both injectable and oral formulations, providing flexibility in administration and catering to patient preferences. As the prevalence of type 2 diabetes continues to rise globally, there is an increasing demand for effective and well-tolerated treatments that can help improve glycemic control and reduce the risk of complications. GLP-1 receptor agonists have gained popularity due to their ability to lower blood sugar levels, promote weight loss, and potentially reduce cardiovascular risk. Hospital pharmacies, retail pharmacies, and other distribution channels play a key role in providing access to GLP-1 receptor agonists to patients with diabetes. With ongoing research and development efforts focused on expanding the therapeutic options within this class of drugs, the GLP-1 receptor agonists segment is poised for significant growth in the incretin-based drugs market.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAstraZeneca PLC, Boehringer Ingelheim Pharmaceuticals Inc, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co. Inc, Novartis AG, Novo Nordisk A/S, Sanofi SA
By Drug
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
AstraZeneca PLC
Boehringer Ingelheim Pharmaceuticals Inc
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co. Inc
Novartis AG
Novo Nordisk A/S
Sanofi SA
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Incretin based Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Incretin based Drugs Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Incretin based Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Incretin based Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Incretin based Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Incretin based Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Incretin based Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Incretin based Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Incretin based Drugs Industry
4.2 Key Market Trends in Incretin based Drugs Industry
4.3 Potential Opportunities in Incretin based Drugs Industry
4.4 Key Challenges in Incretin based Drugs Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Incretin based Drugs Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Incretin based Drugs Market Outlook by Segments
7.1 Incretin based Drugs Market Outlook by Segments, $ Million, 2021- 2030
By Drug
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
8 North America Incretin based Drugs Market Analysis and Outlook To 2030
8.1 Introduction to North America Incretin based Drugs Markets in 2024
8.2 North America Incretin based Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Incretin based Drugs Market size Outlook by Segments, 2021-2030
By Drug
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
9 Europe Incretin based Drugs Market Analysis and Outlook To 2030
9.1 Introduction to Europe Incretin based Drugs Markets in 2024
9.2 Europe Incretin based Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Incretin based Drugs Market Size Outlook by Segments, 2021-2030
By Drug
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
10 Asia Pacific Incretin based Drugs Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Incretin based Drugs Markets in 2024
10.2 Asia Pacific Incretin based Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Incretin based Drugs Market size Outlook by Segments, 2021-2030
By Drug
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
11 South America Incretin based Drugs Market Analysis and Outlook To 2030
11.1 Introduction to South America Incretin based Drugs Markets in 2024
11.2 South America Incretin based Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Incretin based Drugs Market size Outlook by Segments, 2021-2030
By Drug
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
12 Middle East and Africa Incretin based Drugs Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Incretin based Drugs Markets in 2024
12.2 Middle East and Africa Incretin based Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Incretin based Drugs Market size Outlook by Segments, 2021-2030
By Drug
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AstraZeneca PLC
Boehringer Ingelheim Pharmaceuticals Inc
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co. Inc
Novartis AG
Novo Nordisk A/S
Sanofi SA
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Drug
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Incretin based Drugs Market is one of the lucrative growth markets, poised to register a 7.3% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
AstraZeneca PLC, Boehringer Ingelheim Pharmaceuticals Inc, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co. Inc, Novartis AG, Novo Nordisk A/S, Sanofi SA
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume